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Figure 1. Mean concentrations ( SD) of COMP, hsCRP and Cholesterol.Ă
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S78femur, distant from the subchondral bone, on plain radiographs, with
Knee Images Digital Analysis, using an aluminium step wedge as
reference. To allow for adjustment for concurrent radiographic knee
and hip OA, the patellofemoral and tibiofemoral knee compartments
and hips were scored for joint space narrowing, osteophytes, and sub-
chondral sclerosis according to Altman and Burnett.
Results: The majority of subjects did show no or only minimal features
of radiographic knee and hip OA. After adjustment for demographic
variables (i.e. age, gender, and body mass index) and radiographic knee
and hip OA features, bone marker as well as uCTX-II levels, but not the
other cartilage markers, showed associations with peripheral bone
density (standardized betas¼0.103 to 0.183; P¼0.003 to 0.027).
Conclusions: This study warrants more cautious interpretation of CTX-
II as marker of (only) cartilage damage, since our data conﬁrm the
notion that CTX-II may also originate from peripheral bone changes.
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GENETIC MARKERS FOR PREDICTING THE DEVELOPMENT AND
PROGRESSION OF KNEE OSTEOARTHRITIS
A. Mishra, Sr. y, D. Sanghi, II y, A.C. Sharma, Jr. y, D. Parmar, IV z,
R.N. Srivastava V y. yKing George's Med. Univ., Lucknow, India; z Indian
Inst. of Toxicology Res., Lucknow, India
Purpose: The present study was initiated to investigate the association
of SNPs in Estrogen receptor-a (ESR- a), Calmodulin-1 (CALM-1) and
Growth differentiation factor-5 (GDF-5) gene with osteoarthritis knee
(KOA).
Methods: In a case-control study, 300 cases with KOA and an equal
number of age, sex matched healthy controls were included. Cases were
diagnosed using the American college of rheumatology (ACR) guide-
lines of knee osteoarthritis (KOA). Blood was drawn for genomic DNA
isolation, polymerase chain reaction coupled restriction fragments
length polymorphism (PCR-RFLP) was carried out to identify the SNPs.
All statistical analysis was performed with the SPSS software package
(version 16.0 for windows; SPSS Chicago, IL).Results: The variant
genotype of ESR- a, CALM-1 and GDF-5 genes were found to be present
at relatively higher frequency in cases than in the controls. Risk
increased in cases that carried combination of variant genotypes of ESR
a (Btg-AA) and GDF-5(TT) or Calm-1(ApeKI-TG) and GDF-5(TT) or Calm-
1(ApeKI-TG) and ESR a (Btg-AA) resulting 4.00-6.00 fold elevated risk to
KOA. The haplotype T-G-C containing variant of all three polymorphism
of calm-1 gene was also over represented in the cases, increasing the
risk to 3.5 fold in cases. A signiﬁcant association of these variant
genotype was also found with clinical scores of KOA (VAS, WOMAC).
Conclusions: The results suggest that GDF-5, ESR-a and CALM-1 gene
polymorphism is associated with KOA and gene-gene interaction
inﬂuences the development of KOA. Likewise,association of these SNP
with clinical score has again demonstrated that these genetic markers
could be effectively used for predicting development and progression of
osteoarthritis. These can highlighting potential pathways for preven-
tion and therapeutic intervention of knee osteoarthritis.
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BIOMARKERS OF OSTEOARTHRITIS PROGRESSION
F.R. Saunders, K. Yoshida, R.J. Barr, H.M. Macdonald, D.M. Reid,
R.M. Aspden, J.S. Gregory. Univ. of Aberdeen, Aberdeen, United Kingdom
Purpose: to determine whether cartilage oligomeric matrix protein
(COMP), C-reactive protein hsCRP and cholesterol and its metabolites
could be used as biomarkers for osteoarthritis (OA) progression from
plasma samples in a cross sectional study.
Methods: COMP levels were determined from plasma samples (n¼57)
using a COMP ELISA (R&D systems). hsCRP, total cholesterol (TC), HDL
and LDL were determined by standard biochemical detection methods.
Kellgren-Lawrence grade (KLG) was assessed from radiographs by
a single clinician (KY). The knee with the worst KLG was used for
analysis. OA Severity groups were determined by grouping of KLG
(KLG¼0 both knees or KLG¼1 in one knee and KLG¼0 for the other
knee, no OA; KLG¼1 in both knees, mild OA; KLG¼2, moderate OA;
KLG¼3-4 severe OA). Plasma concentrations of all analytes were tested
using the one-way ANCOVA, weighted for KLG or OA severity and
adjusted for age and BMI in SPSS v20.0.
Results: Analysis of COMP levels in plasma showed elevated levels with
increasing KL grade but this was not statistically signiﬁcant (P¼0.159).
When grouped by severity, the increase in COMP levels was notstatistically signiﬁcant (P¼0.230). KLG¼2 had the highest levels of
COMP present (Fig. 1). hsCRP levels were not elevated above normal
limits (10mg/ml) and not related to increasing KLG or severity (P¼0.390
[KLG]; P¼0.286 [OA Severity]). Over 50% of the patient population had
TC levels higher than the recommended normal level of 4 mmol/L. TC
levels were statistically signiﬁcant between KLG (P¼0.046), but not
when related to OA severity (P¼0.053) although the P values are almost
identical. LDL levels were statistically signiﬁcantly increased in relation
to KLG and OA severity (P¼0.025 [KLG]; P¼0.030 [OA severity]). HDL
and the ratio between TC and HDL were not statistically signiﬁcant
when analysed by KLG or by OA severity (HDL P¼0.468 [KLG], P¼0.414
[OA severity]; TC/HDL ratio P¼0.899 [KLG], P¼0.894 [OA severity]).
Conclusions: Total cholesterol and LDL levels from plasma were asso-
ciated with increasing KLG and OA severity. There were elevated levels
of COMP detectable in plasma, however COMP levels were not signiﬁ-
cantly related to KLG or OA severity. There were no detectable levels of
inﬂammation present, as the levels of hsCRP detected were not above
normal levels (10 mg/ml) even with severe OA. hsCRP levels are
decreased by use of NSAIDs, however in this study this information was
not available and we therefore cannot determine whether NSAID use
had any effect on hsCRP levels reported in this population. Elevated
levels of TC and HDL peaked at KLG¼2 and then decreased. This may
indicate that patients with KLG of 3 or 4 are being treated for hyper-
cholesterolaemia, although therewas nomedication history available to
support this. This study indicated that TC and LDL may be surrogate
markers for OA. Currently other markers are being investigated.132
SHORT-TERM SAMPLING STABILITY OF SYNOVIAL FLUID
MEASUREMENTS IN KNEE OSTEOARTHRITIS
C. Jayadev, R. Rout, S. Snelling, P. Hulley, A. Price. Univ. of Oxford, Oxford,
United Kingdom
Purpose: Short-term ﬂuctuations in biomarker measurements unre-
lated to disease progression or treatment would invalidate the utility of
biomarkers for patient assessment. Burden of disease biomarkers in
end-stage knee OA should reﬂect the biological failure associated with
the extent of clinical and structural (radiographic) severity. They should
deﬁne a terminal proﬁle and benchmark that measurements from
earlier stages of disease progress towards. Consequently, one would
expect the synovial ﬂuid (SF) proﬁle of end-stage knee OA to be stable
over short periods of time during which there is no further structural or
clinical deterioration. This has never been formally tested and there are
very few studies with longitudinal SF analyses in knee OA patients. The
study aimed to determine whether SF measurements from patients
with end-stage knee OA remain stable over short periods of time.
Methods: SF was collected from 10 patients with end-stage knee OA
(N¼10) in the clinic room at their pre-operative assessment (POAC). A
second SF sample was collected for each patient at the time of primary
arthroplasty. Each participant completed the Oxford Knee Score (OKS)
and a Visual Analogue Pain score (VASpain) prior to sample collection at
each time point. To assess whether this small sample size was repre-
sentative of patients undergoing primary knee replacement for end-
stage knee OA, a further 15 patients (Reference group) were asked at
random to complete an OKS questionnaire at POAC and on the morning
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between time points. All SF samples underwent identical processing,
storage and preparation. Samples were analysed 9 pro-inﬂammatory
cytokines (IL1b, TNFa, IL6, IL8, IL15, IL2, IL12, IL17 & GMCSF), 4 regula-
tory cytokines (IL1RA, IL4, IL10, IL2R), 7 chemokines (Eotaxin, IP10,
MCP1, MIG, MIP1a, MIP1b, RANTES) and TGFb1, -b2 & -b3. Within-
subject comparison of the OKS and VASpain between time-points was
made using repeat measure statistical tests. P<0.05 was considered
statistically signiﬁcant. The repeatability of matched SF measurements
between time points was assessed for each analyte using the coefﬁcient
of variation (CV), and intraclass correlation coefﬁcient for absolute
agreement (ICC). The acceptable threshold for the interval CV (iCV) was
set at 20%, which is the threshold for acceptable intra- and inter-assay
precision. An ICC between 0.70-0.80 was considered strong absolute
agreement and ICC>0.80was considered excellent absolute agreement.
Results: The median interval between SF measurements was 16.5 days
(IQR 11.25 - 25). There was no signiﬁcant within-subject difference in
OKS or VASpain between time-points. There were no signiﬁcant clinical
or radiographic differences between the Study and Reference groups.
Only 10 analytes were >LOQ in all patient samples to allow meaningful
analysis: 4 pro-inﬂammatory cytokines (IL6, IL8, IL12 & IL15); 3 che-
mokines (Eotaxin, MCP1 & IP10); and the 3 isoforms of TGF-b. The
median iCV was <15% for all analytes and was signiﬁcantly less than
20% for all analytes (p<0.05, one sample Wilcoxon signed rank test).
The ICC was >0.88 for all analytes but one (TGF-b2, ICC¼0.75). For
measurements <LOQ or <LOD, there were no signiﬁcant differences in
the proportion of measurements below each limit between time-points
for any analyte (McNemar's exact test).
Conclusions: There is strong to excellent agreement in SF measure-
ments taken w2 weeks apart in patients with end-stage knee OA. The
study strongly suggests that there is stability in the SF biological proﬁle
over short intervals during which there has been no change in clinical
and radiographic severity. However, one must be cautious in general-
ising the results to all possible SF markers. We therefore advocate the
assessment of short-term sampling stability as part of the validation for
any potential OA biomarker.Figure. Mean log uC2C and uCTX-II concentrations decline between 4 and 16 weeks
after anterior crucicate ligament reconstruction. There is no difference in the slopes of
the biomarkers (p ¼ 0.098).133
URINARY CONCENTRATIONS OF TYPE II COLLAGEN CLEAVAGE
FOLLOWING ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION
F.R. Mora Solis y, T.N. Trumble z, C. Leeuwenburgh y, J.J. Shuster y,
F.M. Cicuttini x, T.L. Chmielewski y. yUniv. of Florida, Gainesville, FL,
USA; zUniv. of Minnesota, St. Paul, MN, USA; xMonash Universtiy,
Melbourne, Australia
Purpose: Knee osteoarthritis (OA) is prevalent following anterior
cruciate ligament reconstruction (ACLR). Urinary concentrations of CTX-
II (uCTX-II), a biomarker of degradation of telopeptides of type II
collagen in articular cartilage, have been shown to be elevated in people
with knee OA. Our previous work has shown that uCTX-II concentra-
tions are also elevated from 4 to 16 weeks after ACLR. Cleavage of type II
collagen triple helices by collagenases has been measured with another
biomarker of articular cartilage degradation (C2C) which is elevated in
the serum of patients with OA. However, little is known about urinary
C2C (uC2C) concentrations in patients with ACLR. A new assay has
recently been developed for quantifying uC2C. Therefore, the purpose of
this study was 1) to examine changes in uC2C concentrations in the
early period after ACLR, 2) compare concentrations to age and sex-
matched controls, and 3) compare changes over time in uC2C and uCTX-
II and their association.
Methods: Urine samples were obtained from 28 subjects with ACLR
(19.6  4.5 yrs) and 28 age and sex-matched controls (19.9 4.3 yrs).
Testing was performed at 4, 8, 12 and 16 wk post surgery in ACLR and
one time point in controls. Early morning, second void urine samples
were obtained and stored at -20oC until analysis. uC2C (IB-C2C-HUSA,
IBEX Technologies) and uCTX-II (Urine CartiLaps, IDS Nordic a/s)
concentrations were analyzed using commercially available enzyme-
linked inmunosorbant assays (ELISA). Both biomarker concentrations
were corrected for creatinine concentration, determined by ELISA
(Caymen Chemical). Concentrations for both biomarkers were log
transformed prior to statistical analysis. Group differences in uC2C
concentrations were examined with paired sample t-tests, and with
linear regression after adjusting for body mass index (BMI). Slopes for
uC2C and uCTX-II across time were determined in ACLR. Paired sample
t-tests examined the differences between the slopes, and PersonProduct Moment correlation determined the association between the
slopes.
Results: Mean (SD) uC2C concentrations in ACLR were 838.2 (876.1),
688.1 (788.1), 775.1 (806.1), and 754.4 (825.6) ng/mmol at 4, 8, 12 and
16 weeks respectively; and in controls was 763.9 (804.7) ng/mmol. Log
uC2C concentrations were signiﬁcantly elevated in ACLR compared to
controls at all testing points, except 8 weeks post-surgery (p ¼ 0.01,
0.071, 0.008, 0.019; respectively). Results were similar after correcting
for BMI (p¼0.007, 0.051, 0.016, 0.018, respectively). Mean slopes for
uC2C (-0.016) and uCTX-II (-0.033) were negative and not signiﬁcantly
different (p ¼ 0.098). There was a moderate correlation between uC2C
and uCTX-II slopes (r¼ 0.652, p<0.01: Figure).
Conclusions: These results demonstrate that uC2C concentrations are
elevated at 4 wks after ACLR, decrease to levels comparable with
controls at 8 wk post ACLR, and become elevated again at 12 wk. The
increase in uC2C concentrations at 12 wk post-surgery coincides with
the typical initiation of advanced rehabilitation. Both uC2C and uCTX-II
concentrations indicate that articular cartilage degradation is initially
elevated after ACLR and improves over time. However, subtle differ-
ences between biomarkers exist. uC2C changes more dramatically over
time suggesting that it may represent acute changes in the joint envi-
ronment better than uCTX-II.134
COMPARISION BETWEEN SENSITIVITY AND SPECIFICITY OF
DIAGNOSTIC POTENTIALS OF CARTILAGE OLIGOMERIC MATRIX
PROTEIN (COMP) AND HYALURONIC ACID (HA) IN KNEE
OSTEOARTHRITIS
U. Shahi y, N.T. Shahi z, S. Singh y, A.K. Gupta y, J. Bajpayi y,
N.R. Anand y. y Era's Lucknow Med. Coll., Lucknow, India; zCareer Inst. of
Med. Sci., Lucknow, India
Purpose: The early detection of osteoarthritis is very favourable in
planning of future treatment. As in subclinical stages, it is only the
cartilaginous component of the ailment that we have to care for. No
joint erosion is usually encountered at such primary stages. Tomeet this
goal, there are researches going on over several biomarkers and genetic
markers to detect the disease in sub clinical stages or even identify the
genetically predisposed cases. There are several biomarkers being
globally studied which include Cartilage Oligomeric Matrix Protein
